Anyone can get TB. In 2019, an estimated 10 million people contracted TB and more than 1.4 million died. Despite the numbers, we know we can end the TB epidemic. It is a matter of scaling up effective programs, dedicating sufficient resources and mobilizing the political will. This report highlights six locations where communities made impressive progress to significantly reduce TB cases and deaths – from California in the United States to Tomsk, Russia and Karachi, Pakistan.
How Can We End the Tuberculosis Epidemic? Lessons from Around the World
Broadly Neutralizing Antibody Combinations
Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.
CAB-LA is a Highly Effective HIV Prevention Option; Now what?
Long-acting injectable cabotegravir (CAB-LA) is a promising new option for HIV prevention. In 2020, early results from two trials—HPTN 083 and HPTN 084—showed CAB-LA was safe and highly effective at preventing HIV when compared to daily oral TDF/FTC (Truvada) in men who have sex with men (MSM), transgender (TG) women and cisgender women. Now what? What questions remain unanswered and what support is needed now to make the growing range of prevention options feasible choices for people who may want and need them?
Broadly Neutralizing Antibody Combinations
As with antiretroviral combinations used in treatment, passive immunization of broadly neutralizing antibodies for prevention may require two or more bNAbs that target different parts of the virus. This graphic outlines the bNAb combinations being explored in early clinical studies.
AMP Study FAQ
From the two trial networks conducting the AMP Study, this document provides answers to commonly asked questions about the VRC01 antibody, details on the study design and more.
Advocate’s Guide To COVID-19 Vaccine Access
The Advocate’s Guide provides plain-language explanations of the necessary components for equitable COVID-19 vaccine access to help inform and support advocates.
Biomedical HIV Prevention Trials: Results, milestones and more
This graphic shows the updated status of large-scale prevention trials through 2022 and the impact of COVID-19 on each trial.
Another version of this graphic is available here (same content, different visual Treatment U=U).
Public Comment from Mitchell Warren, Executive Director, AVAC At the Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting
Comments made by Mitchell Warren to the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting on October 22, 2020 about COVID-19 vaccine development and use authorization.
The Next-Generation of Biomedical Prevention: Now What
Slides presented by AVAC Executive Director Mitchell Warren at the PEPFAR Scientific Advisory Board meeting taking place over October 7-8, 2020.
Understanding the EMA Opinion and Next Steps for the Dapivirine Vaginal Ring
On July 24, 2020, the European Medicines Agency (EMA) announced a positive regulatory opinion from on the Dapivirine Vaginal Ring as an HIV prevention option for cisgender women age 18 and older. This document helps advocates to understand the steps that can and must be taken now that the EMA has provided its opinion. Read it here.